Skip to main content

Advertisement

SpringerLink
Log in

The role of checkpoints in the treatment of GBM

  • Editors' Invited Manuscript
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Targeted immunotherapy is founded on the principle that augmentation of effector T cell activity in the tumor microenvironment can translate to tumor regression. Targeted checkpoint inhibitors in the form of agonist or antagonist monoclonal antibodies have come to the fore as a promising strategy to activate systemic immunity and enhance T cell activity by blocking negative signals, enhancing positive signals, or altering the cytokine milieu. This review will examine several immune checkpoints and checkpoint modulators that play a role in cancer pathogenesis, with an emphasis on malignant gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. doi:10.1038/nrc3239

    Article  CAS  PubMed  Google Scholar 

  2. El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8:234–243. doi:10.1215/15228517-2006-006

    Article  PubMed Central  PubMed  Google Scholar 

  3. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158–2167

    Article  CAS  PubMed  Google Scholar 

  5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294

    Article  CAS  PubMed  Google Scholar 

  7. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12:307–313. doi:10.1038/nrc3246

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8:234–243

    Article  PubMed Central  PubMed  Google Scholar 

  10. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349. doi:10.1016/j.ijrobp.2012.12.025

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13:2158–2167

    Article  CAS  PubMed  Google Scholar 

  12. Davies DC (2002) Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200:639–646

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H (2002) Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104:85–91. doi:10.1007/s00401-002-0524-x

    Article  CAS  PubMed  Google Scholar 

  14. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT Jr, Sampson JH, Dranoff G (2014) Immunotherapy advances for glioblastoma. Neuro Oncol 16:1441–1458. doi:10.1093/neuonc/nou212

    Article  PubMed  Google Scholar 

  15. Galea I, Bechmann I, Perry VH (2007) What is immune privilege (not)? Trends Immunol 28:12–18

    Article  CAS  PubMed  Google Scholar 

  16. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I (2006) T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80:797–801

    Article  CAS  PubMed  Google Scholar 

  17. van Zwam M, Huizinga R, Melief MJ, Wierenga-Wolf AF, van Meurs M, Voerman JS, Biber KP, Boddeke HW, Hopken UE, Meisel C et al (2009) Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) 87:273–286. doi:10.1007/s00109-008-0421-4

    Article  Google Scholar 

  18. Stevenson PG, Hawke S, Sloan DJ, Bangham CR (1997) The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 71:145–151

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12:623–635. doi:10.1038/nri3265

    Article  CAS  PubMed  Google Scholar 

  20. Hersh L, Salzman B (2013) Clinical management of urinary incontinence in women. Am Fam Physician 87:634–640

    PubMed  Google Scholar 

  21. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON et al (2008) Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 57:1279–1289. doi:10.1007/s00262-008-0461-1

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schlager C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE et al (2012) T cells become licensed in the lung to enter the central nervous system. Nature 488:675–679. doi:10.1038/nature11337

    Article  CAS  PubMed  Google Scholar 

  23. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (1987) A new member of the immunoglobulin superfamily—CTLA-4. Nature 328:267–270. doi:10.1038/328267a0

    Article  CAS  PubMed  Google Scholar 

  24. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793–801

    Article  CAS  PubMed  Google Scholar 

  25. Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML (2001) Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol 166:3900–3907

    Article  CAS  PubMed  Google Scholar 

  26. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303–310

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Chen W, Jin W, Wahl SM (1998) Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 188:1849–1857

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225–252

    Article  CAS  PubMed  Google Scholar 

  29. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

    Article  CAS  PubMed  Google Scholar 

  30. Jure-Kunkel M, Masters G, Girit E, Dito G, Lee F, Hunt JT, Humphrey R (2013) Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother 62:1533–1545. doi:10.1007/s00262-013-1451-5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728–734

    CAS  PubMed  Google Scholar 

  32. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57:4036–4041

    CAS  PubMed  Google Scholar 

  33. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH (2010) Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 33:225–235. doi:10.1097/CJI.0b013e3181c01fcb

    Article  CAS  PubMed  Google Scholar 

  34. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. doi:10.1158/0008-5472.CAN-05-3773

    Article  CAS  PubMed  Google Scholar 

  35. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ (2007) CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121:95–105. doi:10.1002/ijc.22607

    Article  CAS  PubMed  Google Scholar 

  36. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr (2012) Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 35:385–389. doi:10.1097/CJI.0b013e3182562d59

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J et al (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075–1081. doi:10.1200/JCO.2008.19.2435

    Article  CAS  PubMed  Google Scholar 

  38. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465. doi:10.1016/S1470-2045(12)70090-6

    Article  CAS  PubMed  Google Scholar 

  39. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616–622. doi:10.1200/JCO.2012.44.6112

    Article  CAS  PubMed  Google Scholar 

  40. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. doi:10.1038/nrc3239

    Article  CAS  PubMed  Google Scholar 

  41. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L (2014) Trial Watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 3:e27297. doi:10.4161/onci.27297

    Article  PubMed Central  PubMed  Google Scholar 

  42. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717. doi:10.1073/pnas.0830997100

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J (2013) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10:14–26. doi:10.1038/nrclinonc.2012.204

    Article  CAS  PubMed  Google Scholar 

  44. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. doi:10.1146/annurev.immunol.26.021607.090331

    Article  CAS  PubMed  Google Scholar 

  45. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765–772

    Article  CAS  PubMed  Google Scholar 

  46. Brauner H, Elemans M, Lemos S, Broberger C, Holmberg D, Flodstrom-Tullberg M, Karre K, Hoglund P (2010) Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol 184:2272–2280. doi:10.4049/jimmunol.0804358

    Article  CAS  PubMed  Google Scholar 

  47. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS et al (2009) PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 106:6303–6308. doi:10.1073/pnas.0809422106

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Weber J (2010) Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 37:430–439. doi:10.1053/j.seminoncol.2010.09.005

    Article  CAS  PubMed  Google Scholar 

  49. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089–1096

    CAS  PubMed  Google Scholar 

  50. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, Nishimura H, Taylor PA (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272–1277

    Article  CAS  PubMed  Google Scholar 

  51. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144. doi:10.1056/NEJMoa1305133

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133. doi:10.1056/NEJMoa1302369

    Article  CAS  PubMed  Google Scholar 

  53. Workman CJ, Vignali DA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33:970–979. doi:10.1002/eji.200323382

    Article  CAS  PubMed  Google Scholar 

  54. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513

    Article  CAS  PubMed  Google Scholar 

  55. Andreae S, Piras F, Burdin N, Triebel F (2002) Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 168:3874–3880

    Article  CAS  PubMed  Google Scholar 

  56. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC et al (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117:3383–3392. doi:10.1172/JCI31184

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC et al (2013) A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 31:707–713. doi:10.1007/s10637-012-9866-y

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, et al (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71-5876-8-71. doi: 10.1186/1479-5876-8-71

  59. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501–4510. doi:10.1182/blood-2010-10-310425

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187–2194. doi:10.1084/jem.20100643

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ (2011) Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 71:3540–3551. doi:10.1158/0008-5472.CAN-11-0096

    Article  CAS  PubMed  Google Scholar 

  62. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O’Reilly RJ, Hsu KC (2009) Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 113:3875–3884. doi:10.1182/blood-2008-09-177055

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Tam YK, Martinson JA, Doligosa K, Klingemann HG (2003) Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5:259–272. doi:10.1080/14653240310001523

    Article  CAS  PubMed  Google Scholar 

  64. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A et al (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678–686. doi:10.1182/blood-2013-08-519199

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Koh PK, Tan BK, Hong SW, Tan MH, Tay AG, Song C, Tan KC (2004) The gluteus maximus muscle flap for reconstruction of sacral chordoma defects. Ann Plast Surg 53:44–49

    Article  PubMed  Google Scholar 

  66. Cheuk AT, Mufti GJ, Guinn BA (2004) Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 11:215–226. doi:10.1038/sj.cgt.7700670

    Article  CAS  PubMed  Google Scholar 

  67. Martinet O, Divino CM, Zang Y, Gan Y, Mandeli J, Thung S, Pan PY, Chen SH (2002) T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 9:786–792. doi:10.1038/sj.gt.3301687

    Article  CAS  PubMed  Google Scholar 

  68. Chen SH, Pham-Nguyen KB, Martinet O, Huang Y, Yang W, Thung SN, Chen L, Mittler R, Woo SL (2000) Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2:39–46. doi:10.1006/mthe.2000.0086

    Article  CAS  PubMed  Google Scholar 

  69. Sznol M, Hodi FS, Margolin K (2008) Phase I Study of BMS-663513, a Fully Human Anti-CD137 Agonist Monoclonal Antibody, in Patients (Pts) with Advanced Cancer (CA). J Clin Oncol (Meeting Abstracts) 26:3007 (Suppl.)

  70. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142. doi:10.1038/ni759

    Article  CAS  PubMed  Google Scholar 

  71. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA et al (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436. doi:10.1371/journal.pone.0010436

    Article  PubMed Central  PubMed  Google Scholar 

  72. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, Collins M, Shevach EM (2004) Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 173:5008–5020

    Article  CAS  PubMed  Google Scholar 

  73. Resenzweig M, Ponte J, Doty D, Guild J, Slavonic M, Ponath P, Vaickus L (2010) Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. J Clin Oncol (Meeting Abstracts) 28:e13028(Suppl.)

  74. Nirschl CJ, Drake CG (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19:4917–4924. doi:10.1158/1078-0432.CCR-12-1972

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280. doi:10.1073/pnas.0915174107

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917–927. doi:10.1158/0008-5472.CAN-11-1620

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Demaria S, Bhardwaj N, McBride WH, Formenti SC (2005) Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63:655–666

    Article  PubMed Central  PubMed  Google Scholar 

  78. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506–511. doi:10.1038/nature01621

    Article  CAS  PubMed  Google Scholar 

  79. Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA (1999) Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 162:5784–5791

    CAS  PubMed  Google Scholar 

  80. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8:239–245

    Article  CAS  PubMed  Google Scholar 

  81. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879–886. doi:10.1016/S1470-2045(12)70324-8

    Article  PubMed  Google Scholar 

  82. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828–833. doi:10.1097/CJI.0b013e3181eec14c

    Article  CAS  PubMed  Google Scholar 

  83. O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L et al (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21:1712–1717. doi:10.1093/annonc/mdq013

    Article  PubMed  Google Scholar 

  84. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825–830. doi:10.1097/CJI.0b013e318156e47e

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  85. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Jennifer E. Kim & Michael Lim

  2. Department of Oncology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Phipps Building Rm 123, Baltimore, MD, 21287, USA

    Michael Lim

Authors
  1. Jennifer E. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.E., Lim, M. The role of checkpoints in the treatment of GBM. J Neurooncol 123, 413–423 (2015). https://doi.org/10.1007/s11060-015-1747-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1747-8

Keywords

Search

Navigation